OnCusp Therapeutics

A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of

One key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up

In a sure sign that the annual J.P. Morgan Healthcare Conference in San Francisco will soon be under way, the waning days of December and the first week of January brought a deluge of new funding anno

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Pays $73m Up Front For Ex-China